Brief: Lineage Enters Into Exclusive Agreement With Neurgain Technologies To Evaluate Novel Delivery System For OPC1 To Treat Spinal Cord Injury
08/02/2021 13:58
Feb 8 (Reuters) - Lineage Cell Therapeutics Inc LCTX.A :
* LINEAGE ENTERS INTO EXCLUSIVE AGREEMENT WITH NEURGAIN
TECHNOLOGIES TO EVALUATE NOVEL DELIVERY SYSTEM FOR OPC1 TO TREAT
SPINAL CORD INJURY
Source text for Eikon: ID:nBw9ztSB0a
Further company coverage: LCTX.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lineage Cell Therapeutics
See all newsLineage Cell Therapeutics Q2 revenue falls but posts profit
Brief: Lineage Cell Therapeutics Q2 Income From Operations USD -8.923 Million
Lineage Cell Therapeutics Q1 net loss widens as expenses rise
Lineage Cell Q4 revenue rises on Genentech collaboration
Brief: Lineage Cell Therapeutics FY Income From Operations USD -36.619 Million